RLAY VS KNSA Stock Comparison

PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentiment
PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentiment

Performance

RLAY
10/100

RLAY returned -58.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

KNSA
100/100

KNSA returned 1.21% in the last 12 months. Based on SPY's performance of -13.13%, its performance is above average giving it a score of 100 of 100.

Technicals

RLAY
64/100

RLAY receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

KNSA
64/100

KNSA receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

RLAY
10/100

RLAY has missed earnings 8 times in the last 20 quarters.

KNSA
10/100

KNSA has missed earnings 7 times in the last 20 quarters.

Profit

RLAY
10/100

Out of the last 19 quarters, RLAY has had 1 profitable quarters and has increased their profits year over year on 1 of them.

KNSA
21/100

Out of the last 20 quarters, KNSA has had 3 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

RLAY
53/100

RLAY has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

KNSA
51/100

KNSA has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.

Analyst Price Targets

RLAY

"Analyst Price Targets" not found for RLAY

KNSA
75/100

4 analysts offer 12-month price targets for KNSA. Together, they have an average target of 0, the most optimistic target put KNSA at 0 within 12-months and the most pessimistic has KNSA at 0.

Sentiment

RLAY

"Sentiment" not found for RLAY

KNSA
68/100

KNSA had a bullish sentiment score of 68.05% across Twitter and StockTwits over the last 12 months. It had an average of 2.00 posts, 0.78 comments, and 1.16 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Relay Therapeutics, Inc. Common Stock Summary

Nasdaq / RLAY
Healthcare
Biotechnology
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Kiniksa Pharmaceuticals, Ltd. Class A Common Stock Summary

Nasdaq / KNSA
Healthcare
Biotechnology
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.